Results 41 to 50 of about 231,349 (305)
Research Progress of Immune Checkpoint Therapy on Colorectal Cancer
Zhongliu Fangzhi Yanjiu, 2021 At present, immunotherapy is in full swing in the treatment of non-small cell lung cancer, melanoma, bladder cancer and other tumor species, and its treatment methods are also diverse, including tumor vaccine treatment, adoptive T cell therapy, immune ...
CAO Qihua, XU Yanbo, XU Dong
doaj +1 more source
Keeping Checkpoint Inhibitors in Check [PDF]
JAMA Network Open, 2019 No ...
Catenacci, Daniel V.T. +2 more
openaire +3 more sources
Checkpoint inhibitors in ovarian cancer: A review of preclinical data
Gynecologic Oncology Reports, 2019 Ovarian cancer is the deadliest gynecologic malignancy, and relapse after initial treatment is frequently fatal. Although ovarian cancer typically has an immunosuppressive tumor microenvironment, a strong intratumoral T cell presence is associated with ...
David W. Doo +2 more
doaj +1 more source
Cardio-toxicity of checkpoint inhibitors [PDF]
Journal of Thoracic Disease, 2018 Immune checkpoint inhibitors (ICIs) have started revolutionizing the treatment of numerous advanced oncological diseases by restoring immune resistance against cancer cells. ICI-associated cardiac adverse effects are rare, but severe. About 50% of cardiac complications comprise myocarditis with variable clinical presentation and a high rate of fatality.
Oliver J, Müller +2 more
openaire +2 more sources
[Checkpoint inhibitors-indications and application in melanoma patients].
, 2020 Since its introduction in 2011 the checkpoint inhibitor ipilimumab, has revolutionized the whole of oncology. After this first major step more checkpoint inhibitors, such as the PD‑1 antibodies nivolumab and pembrolizumab have been developed. The results
Lamos, Cristina, Hunger, Robert
core +1 more source
, 2023 Immune Checkpoint Inhibitors - New Insights and Recent Progress explores a vast array of subjects related to immune checkpoint inhibitors and presents novel insights in this emerging field.
core +1 more source
Immune Checkpoint Inhibitors and Neurotoxicity
Current Neuropharmacology, 2021 : Immune checkpoint inhibitors (ICIs) have recently been used as a promising treatment for cancer, while their toxicity and immune-related side effects can be seen in any organ, including the nervous system. In contrast to other immune-related adverse events (irAEs), neurological irAEs (nAEs) are rare, with varying incidence and symptom complexity ...
Zhao, Zhiyi +4 more
openaire +3 more sources
Pneumonitis and multiple pneumonial infections under combined immune‐checkpoint inhibition
JEADV Clinical Practice, 2023 The introduction of immune checkpoint inhibitors and targeted therapies has revolutionized melanoma treatment. The downside are immune‐mediated adverse events which are frequent and require close patient management.
Kristine E. Mayer +4 more
doaj +1 more source
, 2022 Immunotherapy (IT) in the form of monoclonal antibodies targeting coreceptors involved in the modulation of the immune synapse represents a standard of care for patients with distinct malignancies.
Andréia Cristina de Melo +22 more
core +1 more source
Journal of Immunology Research, 2020 Cancer cells escape immune recognition by exploiting the programmed cell-death protein 1 (PD-1)/programmed cell-death 1 ligand 1 (PD-L1) immune checkpoint axis.
John Apostolidis +4 more
doaj +1 more source